Your browser doesn't support javascript.
The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical COVID-19 Patients: A Prospective Double Controlled Trial.
Adas, G; Cukurova, Z; Yasar, K Kart; Yilmaz, R; Isiksacan, N; Kasapoglu, P; Yesilbag, Z; Koyuncu, I D; Karaoz, E.
  • Adas G; Department of Surgery, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Health Sciences University, Istanbul, Turkey.
  • Cukurova Z; Stem Cell and Gene Therapies Application and Research Center, Health Sciences University, Istanbul, Turkey.
  • Yasar KK; Department of Anesthesia and Intensive Care, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Health Sciences University, Istanbul, Turkey.
  • Yilmaz R; Department of Infectious Diseases, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Health Sciences University, Istanbul, Turkey.
  • Isiksacan N; Department of Anesthesia and Intensive Care, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Health Sciences University, Istanbul, Turkey.
  • Kasapoglu P; Department of Biochemistry and Immunology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Health Sciences University, Istanbul, Turkey.
  • Yesilbag Z; Department of Biochemistry and Immunology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Health Sciences University, Istanbul, Turkey.
  • Koyuncu ID; Department of Infectious Diseases, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Health Sciences University, Istanbul, Turkey.
  • Karaoz E; Istinye University, Faculty of Medicine, Department of Histology & Embryology, Istanbul, Turkey.
Cell Transplant ; 30: 9636897211024942, 2021.
Artículo en Inglés | MEDLINE | ID: covidwho-1285159
ABSTRACT
The aim of this clinical trial was to control the cytokine storm by administering mesenchymal stem cells (MSCs) to critically-ill COVID-19 patients, to evaluate the healing effect, and to systematically investigate how the treatment works. Patients with moderate and critical COVID-19 clinical manifestations were separated as Group 1 (moderate cases, n = 10, treated conventionally), Group 2 (critical cases, n = 10, treated conventionally), and Group 3 (critical cases, n = 10, treated conventionally plus MSCs transplantation therapy of three consecutive doses on treatment days 0, 3, and 6, (as 3 × 106 cells/kg, intravenously). The treatment mechanism of action was investigated with evaluation markers of the cytokine storm, via biochemical parameters, levels of proinflammatory and anti-inflammatory cytokines, analyses of tissue regeneration via the levels of growth factors, apoptosis markers, chemokines, matrix metalloproteinases, and granzyme-B, and by the assessment of the immunomodulatory effects via total oxidant/antioxidant status markers and the levels of lymphocyte subsets. In the assessment of the overall mortality rates of all the cases, six patients in Group-2 and three patients in Group-3 died, and there was no loss in Group-1. Proinflammatory cytokines IFNγ, IL-6, IL-17A, IL-2, IL-12, anti-inflammatory cytokines IL-10, IL-13, IL-1ra, and growth factors TGF-ß, VEGF, KGF, and NGF levels were found to be significant in Group-3. When Group-2 and Group-3 were compared, serum ferritin, fibrinogen and CRP levels in Group-3 had significantly decreased. CD45 +, CD3 +, CD4 +, CD8 +, CD19 +, HLA-DR +, and CD16 + / CD56 + levels were evaluated. In the statistical comparison of the groups, significance was only determined in respect of neutrophils. The results demonstrated the positive systematic and cellular effects of MSCs application on critically ill COVID-19 patients in a versatile way. This effect plays an important role in curing and reducing mortality in critically ill patients.
Asunto(s)
Palabras clave

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Mesenquimatosas / COVID-19 Tipo de estudio: Estudio de cohorte / Estudio experimental / Estudio observacional / Estudio pronóstico / Ensayo controlado aleatorizado / Revisión sistemática/Meta análisis Tópicos: Vacunas Límite: Adulto / Femenino / Humanos / Masculino / Middle aged Idioma: Inglés Revista: Cell Transplant Asunto de la revista: Trasplante Año: 2021 Tipo del documento: Artículo País de afiliación: 09636897211024942

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Mesenquimatosas / COVID-19 Tipo de estudio: Estudio de cohorte / Estudio experimental / Estudio observacional / Estudio pronóstico / Ensayo controlado aleatorizado / Revisión sistemática/Meta análisis Tópicos: Vacunas Límite: Adulto / Femenino / Humanos / Masculino / Middle aged Idioma: Inglés Revista: Cell Transplant Asunto de la revista: Trasplante Año: 2021 Tipo del documento: Artículo País de afiliación: 09636897211024942